Mantle cell lymphoma Trials in Nashville, United States
Conditions / Mantle cell lymphoma / Nashville, United States
Mantle cell lymphoma has been the subject of sustained clinical investigation across multiple research sites.
32 total trials for this combination
Showing top 10 of 32 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03740529 | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | COMPLETED | PHASE1/PHASE2 |
| NCT05006716 | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies | RECRUITING | — |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | RECRUITING | — |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | COMPLETED | PHASE1/PHASE2 |
| NCT01415752 | Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06742996 | A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) | RECRUITING | — |
| NCT01000753 | Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma | COMPLETED | — |
| NCT01597778 | Double Cord Versus Haploidentical (BMT CTN 1101) | COMPLETED | PHASE3 |
| NCT01776840 | A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma | COMPLETED | PHASE3 |
| NCT03267433 | Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission | ACTIVE_NOT_RECRUITING | PHASE3 |